Menopause Matters frames treatment as individualized, not one-size-fits-all

In 2025, the U.S. Food and Drug Administration removed broad boxed warnings from menopausal HRT products to clarify risk considerations. Perimenopause treatment turns on design choices, and Menopause Matters organizes those choices around the person, not just the symptom.

Why individualised care matters

The central idea in UK guidance is not complicated: one size does not fit all. NICE recommends individualised care and shared decision-making, and its updated menopause guidance states that HRT is effective for menopausal symptoms but should not be used to prevent cardiovascular disease or dementia. NICE also published a discussion aid to help women and clinicians talk through risks and benefits without flattening the decision into a simple yes-or-no.

That approach matches the way patient-facing resources are structured. Menopause Matters groups information around the practical choices that actually change outcomes: which hormones are used, how they are given, how doses are adjusted, and where non-hormonal approaches may fit. The British Menopause Society has been doing the same kind of myth-busting since it was established in 1989.

What the main decision points really are

NHS guidance covers HRT with estrogen, progestogen or both, taken as tablets, patches, gel, spray or vaginal products, including rings, pessaries or cream. The best type depends on factors such as hysterectomy status, stage of menopause and personal preferences, which is why two women with the same hot flushes may end up with very different prescriptions.

Route matters as much as hormone choice. Different routes of estrogen have different metabolic effects, including effects on clotting factors and blood fats, so the delivery method is not just a convenience issue. Tablets may carry a higher risk of blood clots than patches, gel or spray, although the overall risk remains small. For many women, that is the point at which a clinician starts talking about route, not just dose.

This is where a symptom diary can help. If your main problem is night sweats, brain fog, anxiety, vaginal dryness, bleeding changes or a mix of all of them, the pattern helps shape the plan. Menopause is not a single complaint, and treatment usually works better when the regimen is matched to the dominant symptom cluster.

Bleeding changes, womb protection and Mirena

Bleeding is one of the clearest signs that the conversation needs to be individualised. In perimenopause, cycles can become erratic long before periods stop completely, and the progestogen part of treatment has to protect the womb lining when estrogen is used. Mirena can provide womb-lining protection while allowing systemic estrogen to be tailored to the individual’s needs.

That flexibility matters because some women want a simpler regimen, while others want fewer bleeding days. Menopause Matters puts the share at 30% to 60% of women who have no bleeding over time when Mirena is used as part of an HRT regimen.

Hysterectomy status matters so much. If the uterus has been removed, the regimen is different from the one used when the womb is still present. If you still have a uterus and your bleeding pattern is changing, the question is not simply whether you want HRT, but which progestogen, at what dose, and by what route, will protect the lining while keeping symptoms under control.

Timing, age and why this comes up in working life

NICE’s clinical knowledge summary puts the median age at final menstrual period at 50 years, with an interquartile range of 48 to 53 years. It also estimates that about 2% of women experience premature menopause before age 40. Perimenopause and menopause are often discussed as if they arrive at the edges of life, but they can land squarely in the middle of career, caregiving and financial planning.

That is one reason UK policy discussions have treated menopause and perimenopause as workplace and public-health issues, not just private symptoms. The Department for Work and Pensions has been part of that conversation, and the policy angle is practical: if symptoms can affect sleep, concentration, mood and bleeding, then access to clear, evidence-based information affects work as well as health.

Why the old caution still shapes the new conversation

Removing those broad boxed warnings does not make HRT risk-free, and it does not erase the early-2000s safety scare that still shapes public perception. It does, however, reflect a move toward explaining risk in context rather than treating all menopausal hormone therapy as if it carried the same meaning for every patient.

For a woman trying to decide whether to start treatment, the useful questions are usually concrete: What symptoms am I treating? How has my bleeding changed? Do I still have a womb? Which route best fits my risk profile and preferences? What is available locally, and what can I realistically access?